Comprehensive landscape of gastric cancer-targeted therapy and identification of CSNK2A1 as a potential target
The high failure rate of GC clinical trials highlights the need for a more scientific and precise approach in target identification and clinical trial design. CSNK2A1 emerges as a promising therapeutic target for GC, and its expression level could potentially serve as a biomarker for predicting sensitivity to CX-4945 treatment. Further research is warranted to elucidate the underlying molecular mechanisms and validate the clinical significance of CSNK2A1 in GC therapy.
Authors
- Xiangyang Xue (ORCID: https://orcid.org/0000-0002-4897-9209)
- Shiyu Feng (ORCID: https://orcid.org/0000-0003-2455-190X)
- Liang Zhang (ORCID: https://orcid.org/0000-0002-4813-2251)
- Jiaqi Yang (ORCID: https://orcid.org/0000-0001-7715-7864)
- Xian Shen (ORCID: https://orcid.org/0000-0003-1164-4832)
- Tao You (ORCID: https://orcid.org/0000-0003-2100-3318)
- Yingpeng Huang (ORCID: https://orcid.org/0000-0002-5595-0885)
- Qunjia Huang
Institutions
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
Publication Details
- Journal
- Heliyon
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1016/j.heliyon.2024.e36205
- Citations
- 4
- Primary Topic
- RNA Research and Splicing
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- National Natural Science Foundation of China
- Recruitment Program of Global Experts